The global Drugs for Schistosomiasis market generated revenue of around USD 73.4 million in 2020 and anticipated to grow at a CAGR of over 5.6% during the forecast period from 2021 to 2027 to reach around USD 103.4 million in 2027.
Schistosomiasis is a disease that affects the intestines or urogenital areas due to the infection caused by parasitic worms present in water bodies. It is mostly found in Sub-Saharan Africa, Caribbean islands, South East Asia, and the Middle east. Abdominal pain, presence of blood in urine, presence of blood in the stool, enlarged liver, and difficulty in passing urine are the major symptoms of chronic schistosomiasis. The chronic infection might lead to bladder cancer or liver fibrosis.
Key Trends in Global Drugs for Schistosomiasis Market
The increasing number of Schistosomiasis cases is driving the market growth
Schistosomiasis affects nearly 240 million people worldwide, according to the World Health Organization. The majority of those infected are from Africa. The infection is more prevalent in the world’s subtropical and tropical regions. It affects communities that do not have access to potable water as well as communities that live near polluted water streams. Another factor contributing to the spread of schistosomiasis is poor sanitation. In many countries, a lack of adequate healthcare facilities prevents early detection of Schistosomiasis. Schistosomiasis is found in nearly 78 countries around the world. Pollution in waterways promotes the growth of the various Schistosoma species that cause infection.
Browse the full report at https://www.credenceresearch.com/report/drugs-for-schistosomiasis-market
Impact of COVID 19 on Global Drugs for Schistosomiasis Market
COVID 19 had a significant impact on the global Schistosomiasis drug market. As the pandemic spread, governments around the world imposed lockdowns and strict regulations on the movement of people and goods. Initially, the output of the drug manufacturing plants was reduced as a result of the regulations. Because hospitals were focused on treating COVID 19 patients, disease detection and treatment, such as Schistosomiasis, were delayed. When compared to 2019, COVID 19 resulted in a decrease in demand for schistosomiasis drugs and a 2.5 percent decrease in total revenue generated by the global schistosomiasis drugs market.
Global Drugs for Schistosomiasis Market by Drug Type Insights
Artemisinins, Biltricide, Corticosteroids, Metrifonate, Trioxolanes, Praziquantel, and Oxamniquine are the major drugs for schistosomiasis. With nearly 24.3% share, Praziquantel accounted for the majority share of the total revenue generated by the global Schistosomiasis market in 2020.
Praziquantel dominate the global Drugs for Schistosomiasis market
Global Drugs for Schistosomiasis Market by Application Insights
Schistosoma Haematobium, Schistosoma Japonicum, and Schistosoma Mansoni, mostly causes Schistosomiasis. These three species accounted for the majority of the application of drugs for schistosomiasis in 2020. The other three species are limited to certain geographical areas.
Global Drugs for Schistosomiasis Market by Distribution Channel Insights
Hospital pharmacy, online pharmacy, and retail pharmacy are the three major distribution channels in the drugs for the schistosomiasis market. With nearly 32.1 %, hospital pharmacy accounted for the majority of revenue generated in the market, as patients rely heavily on it for the drugs, upon receiving a prescription from the doctors.
Global Drugs for Schistosomiasis Market by Regional Insights
Africa was the largest market of drugs for Schistosomiasis in 2020. They accounted for nearly 28.9% share in overall revenue generated globally. There are nearly 120 million people in sub-Saharan Africa with symptoms related to schistosomiasis. Nearly 20 million people are having chronic conditions. In Africa, the infection rate of schistosomiasis is driven by a lack of access to clean water and the presence of polluted water sources. Schistosomiasis affects a large number of people in the Middle East. The number of schistosomiasis patients is rising in Latin American countries with large populations. The presence of a large number of polluted water streams and populations living near waterbodies contribute to the increase in schistosomiasis patients in the Asia-Pacific region. The improvement of healthcare systems in Asia-Pacific countries is improving infection detection.
Download Free Sample PDF including full TOC, Tables and Figures@ https://www.credenceresearch.com/sample-request/60309
Global Drugs for Schistosomiasis Market Competitive Landscape
Most prominent players in the global drugs for schistosomiasis include Bayer AG, Chandra Bhagat Pharma Ltd, EIPICO, Merck & Co Inc, Pfizer Inc, Par Pharmaceutical Inc, Samarth Pharma Pvt Ltd, Sanofi SA, Shin Poong Pharm Co Ltd, and Taj Pharmaceuticals Ltd among others. The report covers very detailed profiles of these key players.
Market Segmentation
Global Drugs for Schistosomiasis Market by Drug Type, 2015 – 2027
· Artemisinins
· Biltricide
· Corticosteroids
· Metrifonate
· Trioxolanes
· Praziquantel
· Oxamniquine
· Others
Global Drugs for Schistosomiasis Market by Application, 2015 – 2027
· Schistosoma Guineensis
· Schistosoma Haematobium
· Schistosoma Intercalatum
· Schistosoma Japonicum
· Schistosoma Mansoni
· Schistosoma Mekongi
Global Drugs for Schistosomiasis Market by Distribution Channel, 2015 – 2027
· Hospital Pharmacy
· Online Pharmacy
· Retail Pharmacy
Global Drugs for Schistosomiasis Market by Region, 2015 – 2027
· North America
· Europe
· Asia Pacific
· Latin America
· Middle East and Africa
Global Drugs for Schistosomiasis Market: Key Players
· Bayer AG
· Chandra Bhagat Pharma Ltd
· EIPICO
· Merck & Co Inc
· Pfizer Inc
· Par Pharmaceutical Inc
· Samarth Pharma Pvt Ltd
· Sanofi SA
· Shin Poong Pharm Co Ltd
. Taj Pharmaceuticals Ltd
Download Free Sample PDF including full TOC, Tables and Figures@ https://www.credenceresearch.com/sample-request/60309
About Us
Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non-legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives.
Media Contact
Name: Chris Smith
Address: 105 N 1st ST #429,
SAN JOSE, CA 95103 US
(US/CANADA) Ph.: +1-800-361-8290
E-mail: sales@credenceresearch.com
Contact Information:
Media Contact Name: Chris Smith Address: 105 N 1st ST #429, SAN JOSE, CA 95103 US (US/CANADA) Ph.: +1-800-361-8290 E-mail: sales@credenceresearch.com
Tags:
, Financial Content, Reportedtimes, IPS, iCN Internal Distribution, Extended Distribution, Research Newswire, English
Contact Information:
Media Contact
Name: Chris Smith
Address: 105 N 1st ST #429,
SAN JOSE, CA 95103 US
(US/CANADA) Ph.: +1-800-361-8290
E-mail: sales@credenceresearch.com
The post Drugs for Schistosomiasis market is anticipated to reach around USD 103.4 MN in 2027 | Credence Research appeared first on Financial Market Brief.
